# Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

> **NCT07657793** · PHASE2,PHASE3 · RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 164 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Immune Thrombocytopenia

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07657793
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-07
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657793, "Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*